Clinical Trial

Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
To demonstrate that anlotinib hydrochloride capsules combined with TQB2450 injection can significantly prolong progression-free survival (PFS) compared with chemotherapy in patients with recurrent or metastatic endometrial cancer that is non- microsatellite instability high (non-MSI-H) or DNA mismatch repair deficient (non-dMMR).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-21.
Trial Details
NCT Number NCT06475599
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Endometrial Cancer
Enrollment 420 participants
Start Date 2024-07
Primary Completion 2027-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2024-06-27